Cesca Therapeutics Inc. announced that its device subsidiary, ThermoGenesis, has signed a license agreement with IncoCell Tianjin, a wholly-owned subsidiary of Boyalife Group, for CAR-T related and other cellular processing CDMO services.
Under the agreement, ThermoGenesis has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X-Series™ cellular processing research devices, consumables, and kits for use in the conduct of CDMO operations in certain Asia Pacific countries. In exchange, ThermoGenesis is entitled to a percentage of IncoCell’s gross contract development revenues, including any potential upfront payments, future milestones or royalty payments.
“China is among the leading markets for CAR-T developers, and together with the U.S., represent the two countries with the highest number of ongoing CAR-T clinical trials,” said Dr. Chris Xu, chief executive officer of Cesca. “This agreement with IncoCell signifies our first CDMO collaboration, and is consistent with our goal of expanding beyond off-the-shelf cellular processing solutions into higher-value contract manufacturing and development services.”
Territories covered under the IncoCell agreement consist of the People’s Republic of China, Japan, South Korea, Taiwan, Hong Kong, Macau, Singapore, Malaysia, Indonesia and India.
